NCT00006256View on ClinicalTrials.gov

Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 8, 2000

Primary Completion Date

November 30, 2005

Study Completion Date

November 20, 2023

Conditions
Breast Cancer
Interventions
DRUG

paclitaxel

Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.

PROCEDURE

adjuvant therapy

doxorubicin and cyclophosphamide adjuvant regimen

RADIATION

radiation therapy

Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.

Trial Locations (9)

44024

UH-Geauga, Chardon

44060

UH-LUICC, Mentor

44121

UH-Green Road, South Euclid

44122

UH-Chagrin Highlands, Orange

44124

UH-Monarch, Mayfield Heights

44130

UH-Southwest, Middleburg Heights

44145

UH-Westlake, Westlake

44708

UH-CantonMercy, Canton

44106-5055

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT00006256 - Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer | Biotech Hunter | Biotech Hunter